Great rundown on the position(s) of Merck, BMS and Roche with respect to the FDA review taking place tonight.
my interpretation (fwiw dyor) is that it will bring significant pressure onto the owners of the leading immuno oncolytic productscts to show value and improved OSR, to maintain their market standing and revenues...
a good read if you want to be familiar with the competition in the Monoclonal antibody space.
enjoy, :-)
://www.fiercepharma.com/pharma/merck-bristol-myers-roche-to-face-fda-scrutiny-for-pd-1-l1-accelerated-approvals-at-adcom-aWhat are Merck, Bristol Myers and Roche planning for the big FDA cancer approval
review? Here's our rundownRoche's Tecentriq, Bristol Myers Squibb's Opdivo and Merck's Keytruda will be under the microscope as the FDA convenes a multiday committee meeting to reconsider accelerated approvals granted to the cancer drugs. (FDA)
apo!
https
- Forums
- ASX - By Stock
- Media Thread
Great rundown on the position(s) of Merck, BMS and Roche with...
-
- There are more pages in this discussion • 13,710 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.7¢ |
Change
0.001(1.79%) |
Mkt cap ! $418.9M |
Open | High | Low | Value | Volume |
5.6¢ | 5.7¢ | 5.4¢ | $461.9K | 8.347M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 1082545 | 5.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 603058 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 1082545 | 0.055 |
11 | 751779 | 0.054 |
16 | 3014424 | 0.053 |
22 | 1646348 | 0.052 |
17 | 4842977 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.057 | 603058 | 6 |
0.058 | 1247143 | 8 |
0.059 | 324318 | 2 |
0.060 | 1512398 | 12 |
0.061 | 1091000 | 7 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |